On this page
Hemimegalencephaly
This condition typically presents in infancy with drug-resistant seizures and developmental delays. Most cases arise from somatic mutations affecting brain growth pathways, meaning the genetic change occurs during early development and is not inherited from parents.
Overview
Hemimegalencephaly describes a striking neurological malformation characterised by enlargement and abnormal organisation of one cerebral hemisphere. The affected hemisphere shows disordered brain architecture, including abnormal layering of the cortex, unusual cell types, and disrupted neural networks. This structural disarray interferes with normal brain function and typically leads to severe epilepsy that begins in the first year of life.
The condition is rare, though exact prevalence figures are not well established. Because the brain malformation is present from birth, symptoms generally emerge during infancy. The overgrown hemisphere may contain clusters of abnormal neurons and other cell types that generate excessive electrical activity, triggering seizures that are often difficult to control with medication. Developmental progress is usually affected, with most children experiencing delays in motor skills, learning, and cognitive development.
Hemimegalencephaly falls within a broader spectrum of brain overgrowth disorders linked to disrupted cell signalling during foetal development. Understanding the genetic basis of this condition has improved in recent years, with identification of specific gene variants that drive excessive brain growth in the affected hemisphere.
Symptoms & clinical features
Seizures represent the most prominent clinical feature of hemimegalencephaly, typically beginning within the first few months of life. These seizures are often frequent, varied in type, and prove resistant to standard antiepileptic medications. Infantile spasms are particularly common, though other seizure patterns may also occur. The intensity and frequency of seizures can significantly impact quality of life and contribute to further developmental difficulties.
Developmental delays affect most children with this condition. Motor milestones such as sitting, crawling, and walking are often delayed, and many children develop hemiparesis (weakness on one side of the body) affecting the side opposite to the enlarged hemisphere. Cognitive development is typically impaired, though the degree varies amongst individuals. Some children may also experience visual impairment, behavioural challenges, and difficulties with feeding or swallowing. As children grow, the enlarged hemisphere may become visibly apparent, sometimes causing asymmetry of the head or face.
Video: Genetics 101
Affected organs
Hemimegalencephaly is confined to the brain, specifically affecting one cerebral hemisphere. The structural abnormalities include an enlarged hemisphere with thickened cortex, blurred boundaries between grey and white matter, and disordered neuronal migration. Microscopic examination reveals abnormal cell populations, including dysmorphic neurons and balloon cells that are characteristic of cortical dysplasia. The overlying skull on the affected side may also show compensatory changes, sometimes appearing enlarged or asymmetric to accommodate the increased brain volume beneath.
Risks & severity
Hemimegalencephaly represents a severe condition with substantial impact on neurological function and quality of life. The drug-resistant epilepsy that characterises this disorder carries risks including injury during seizures, sudden unexpected death in epilepsy (SUDEP), and progressive cognitive decline if seizures remain uncontrolled. The degree of developmental impairment varies, but most affected individuals require lifelong support and supervision.
Severity correlates partly with the extent of brain involvement and how early seizures begin. Some children experience catastrophic epilepsy with near-constant seizure activity, whilst others have somewhat better seizure control. Long-term outcomes depend heavily on how well seizures can be managed and on the intensity of supportive therapies. Without effective seizure control, children face ongoing risks to brain development and safety.
Genetic causes
Hemimegalencephaly most commonly arises from somatic mutations - genetic changes that occur during early brain development rather than being inherited. Three genes within the PI3K-AKT-MTOR signalling pathway are most frequently implicated: PIK3CA, AKT3, and MTOR. This cellular pathway normally regulates growth, cell division, and survival. When pathogenic variants arise in genes encoding components of this pathway, affected brain cells receive inappropriate growth signals, leading to excessive proliferation and disorganised brain architecture.
PIK3CA encodes the p110 alpha protein, which forms the catalytic core of the PI3K enzyme. This enzyme integrates signals that direct how cells grow, survive, and manage energy resources. AKT3 produces a kinase protein particularly important in foetal brain development, whilst MTOR encodes a central regulator that coordinates multiple growth pathways. Because these mutations occur as somatic events during foetal development, they are present only in a subset of brain cells (mosaicism), typically affecting one hemisphere whilst sparing the other. The mutation is not present in other body tissues and cannot be passed to future generations.
The mosaic distribution helps explain why only one hemisphere is affected. Genetic testing of blood samples may not detect the mutation, as it may be confined to brain tissue. Advanced testing of affected brain tissue removed during surgery can sometimes identify the specific variant, though this is not always necessary for diagnosis.
- AKT3 AKT serine/threonine kinase 3
- MTOR mechanistic target of rapamycin kinase
- PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaThe PIK3CA gene provides instructions for a crucial enzyme involved in fundamental cellular processes such as growth, division, and survival.
Inheritance pattern
Hemimegalencephaly typically results from somatic mutations that occur spontaneously during early brain development. These genetic changes are not inherited from parents and arise as new events in the developing foetus. Because the mutation occurs after conception and affects only certain brain cells, it represents mosaicism - the presence of two genetically distinct cell populations within the same individual.
This somatic origin means the condition does not run in families and parents of an affected child are not at increased risk of having another child with hemimegalencephaly. The affected individual's risk of passing the condition to their own children is negligible, as the mutation is confined to brain tissue and not present in reproductive cells. Genetic counselling can help families understand this pattern and address concerns about recurrence or inheritance.
Diagnosis & testing
Diagnosis of hemimegalencephaly relies primarily on neuroimaging, particularly magnetic resonance imaging (MRI) of the brain. MRI scans reveal the characteristic enlargement of one hemisphere along with structural abnormalities including cortical thickening, abnormal grey-white matter boundaries, and disorganised brain architecture. These imaging findings, combined with clinical features such as early-onset seizures and developmental delays, typically establish the diagnosis.
Genetic testing may be pursued to identify pathogenic variants in PIK3CA, AKT3, MTOR, or related genes, though detection can be challenging because mutations are somatic and mosaic. Testing of DNA from blood may yield negative results even when a causative variant is present in brain tissue. More sensitive testing techniques or analysis of affected brain tissue obtained during surgery can improve detection rates. Within NHS genetic services, referral to clinical genetics may be appropriate for genetic counselling and to explore testing options. Electroencephalography (EEG) is routinely performed to characterise seizure patterns and guide treatment decisions.
Management & lifestyle
Management of hemimegalencephaly focuses on controlling seizures and supporting development. Antiepileptic medications are typically tried first, though seizures often prove resistant to medical therapy alone. When medications fail to provide adequate seizure control, surgical options may be considered. Hemispherectomy or hemispherotomy - procedures that disconnect or remove the affected hemisphere - can dramatically reduce or eliminate seizures in carefully selected candidates. These surgeries are major undertakings requiring assessment by specialist paediatric neurosurgery teams.
Supportive therapies play a central role throughout life. Physiotherapy, occupational therapy, and speech and language therapy address motor delays, functional skills, and communication challenges. Educational support tailored to individual abilities helps maximise developmental potential. Families often require access to respite care, specialist equipment, and multidisciplinary coordination. Regular follow-up with paediatric neurology, epilepsy specialist nurses, and developmental paediatricians ensures comprehensive care and monitoring for complications. Newer targeted therapies that inhibit the PI3K-AKT-MTOR pathway are under investigation, though these remain experimental and are not yet part of standard UK clinical practice.
UK care pathway
Children with suspected hemimegalencephaly are typically referred through paediatric neurology services after presenting with early-onset seizures or developmental concerns. Neuroimaging confirms the diagnosis, prompting involvement of specialist epilepsy teams and, where appropriate, paediatric neurosurgery centres. Referral to clinical genetics services may be arranged to discuss genetic testing, explain the somatic nature of the condition, and provide family counselling. Genetic counsellors can address questions about recurrence risk and implications for other family members.
Long-term care involves coordination across multiple NHS specialties, often with support from community paediatric teams and neurodisability services. Families may benefit from connection to patient support organisations and access to specialist educational resources. The multidisciplinary approach ensures that both medical and developmental needs are addressed throughout childhood and into adulthood.
Frequently asked questions
Will my child's seizures improve as they get older?
Seizures in hemimegalencephaly are typically severe and resistant to medication. Without surgical intervention, seizures often persist and may worsen over time. Hemispherectomy surgery can dramatically improve or eliminate seizures in many carefully selected candidates, offering the best chance for seizure control and developmental progress.
Could I have another child with hemimegalencephaly?
The genetic changes causing hemimegalencephaly occur spontaneously during brain development and are not inherited from parents. Your risk of having another affected child is very low, essentially the same as the general population risk. Genetic counselling can provide personalised information based on your family's situation.
Why didn't genetic testing find a mutation in my child?
The mutations causing hemimegalencephaly are somatic and mosaic, meaning they occur during development and may be present only in brain tissue. Standard blood tests might not detect these changes. More sensitive testing techniques or analysis of brain tissue can sometimes identify the variant, though diagnosis usually relies on clinical features and brain imaging.
What does hemispherectomy surgery involve and is it safe?
Hemispherectomy involves disconnecting or removing the affected brain hemisphere to stop seizures. Whilst this is major surgery with inherent risks, specialist paediatric neurosurgery centres have extensive experience with these procedures. The remaining hemisphere can often compensate remarkably well, particularly in young children. Neurosurgery teams typically discuss specific risks, benefits, and expectations based on individual circumstances.
Are there any new treatments being researched for hemimegalencephaly?
Researchers are investigating targeted therapies that inhibit the PI3K-AKT-MTOR pathway, as this signalling system drives the brain overgrowth in hemimegalencephaly. These treatments remain experimental and are not yet available as standard care in the UK, but they represent a promising direction for future therapeutic options.
References
- Gerasimenko A, Baldassari S, Baulac S. mTOR pathway: Insights into an established pathway for brain mosaicism in epilepsy. Neurobiology of disease. 2023. PMID: 37149062
- Adam MP, Bick S, Mirzaa GM. DEPDC5-Related Epilepsy. 1993. PMID: 27683934
- Crino PB. Focal Cortical Dysplasia. Seminars in neurology. 2015. PMID: 26060899
- Ream M. Hypomelanosis of Ito. Handbook of clinical neurology. 2015. PMID: 26564088
- Laura FS. Epidermal nevus syndrome. Handbook of clinical neurology. 2013. PMID: 23622186
- Mirzaa GM, Paciorkowski AR. Introduction: Brain malformations. American journal of medical genetics. Part C, Seminars in medical genetics. 2014. PMID: 24853778
- Mirzaa GM, Poduri A. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology. American journal of medical genetics. Part C, Seminars in medical genetics. 2014. PMID: 24888963
- Puka K, Jones M, Mathern GW. Functional cognitive and language outcomes after cerebral hemispherectomy for hemimegalencephaly. Epilepsia. 2021. PMID: 34608636